ROS1 and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphoma kinase (ALK) and c-ros oncogene1 (ROS1) genes have been shown in multiple studies to have an increased risk of VTE events.